Investigational PT010 Seen to Improve Lung Function of COPD Patients in Phase 3 Trial
AstraZeneca’s triple combination therapy PT010 (budesonide/glycopyrrolate/formoterol fumarate) improved lung function and reduced the rate of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in a Phase 3 trial, compared with dual combination therapies. Results of the trial were published in the study, “Triple…